Polaryx Therapeutics (PLYX) – Investment Analysts’ Recent Ratings Updates

Polaryx Therapeutics (NASDAQ: PLYX) has recently received a number of price target changes and ratings updates:

• 7/12/2026 – Polaryx Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/10/2026 – Polaryx Therapeutics was upgraded by Zacks Research to “hold”.
• 7/9/2026 – Polaryx Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $7.00 price target on the stock.
• 7/1/2026 – Polaryx Therapeutics was upgraded by Weiss Ratings from “sell (e-)” to “sell (e)”.

Insider Transactions at Polaryx Therapeutics

In other news, CEO Alex Keun Mo Yang bought 88,453 shares of Polaryx Therapeutics stock in a transaction on Wednesday, May 27th. The stock was purchased at an average cost of $4.07 per share, with a total value of $360,003.71. Following the purchase, the chief executive officer directly owned 24,233,249 shares of the company’s stock, valued at approximately $98,629,323.43. This trade represents a 0.37% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.